Pharmacy DX Solution 'enpas' Surpasses 10 Million Patients Receiving Health Support Information, Enhancing Support for Additional Fees and Operational Efficiency in Preparation for the 2026 Dispensing Fee Revision
Pharmacy DX 'enpas' exceeds 10 million patients receiving health support information, strengthening its response to dispensing fee revisions.
📋 Article Processing Timeline
- 📰 Published: April 1, 2026 at 00:00
- 🔍 Collected: April 1, 2026 at 01:06 (1h 6m after Published)
- 🤖 AI Analyzed: April 16, 2026 at 15:20 (374h 13m after Collected)
DigiQ Inc. (Headquarters: Minato-ku, Tokyo; CEO: Kazuyuki Furuya; COO: Yusuke Imai), a group company of CARTA HOLDINGS Inc. that develops retail DX and healthcare DX businesses, announces that its DX solution for dispensing pharmacies, 'enpas,' has surpassed a cumulative total of 10 million patients (※2) who have received personalized health support information (※1).
（※1）Refers to explanations of side effects, advice for maintaining health, etc., tailored to the patient's condition and medication status.
（※2）Actual results as of March 2026.
Amidst the stricter evaluation of 'interpersonal services' due to the 2026 (Reiwa 8) dispensing fee revision, 'enpas' significantly reduces administrative tasks for pharmacists. Cases show an approximately fivefold increase in information provided to hospitals, and a substantial expansion in the number of claims for specific drug management and guidance fees 1 and 3. By maximizing the evaluation of 'interpersonal services,' which is crucial for pharmacy management, through high-quality interventions, 'enpas' simultaneously achieves stability in pharmacy operations.
The 2026 (Reiwa 8) Dispensing Fee Revision and a Turning Point for Pharmacy Management
The 2026 (Reiwa 8) dispensing fee revision further clarifies the shift in evaluation from the 'act' of dispensing itself to the 'functions and achievements' provided by pharmacies. Therefore, the need to enhance interpersonal services and refine the value of pharmacies as 'chosen community pharmacies' is greater than ever.
In response to these changes in the management environment, 'enpas' strongly supports the 'systematization of high-quality interventions' that directly link pharmacists' expertise to revenue, by accumulating case studies and sharing know-how with partner pharmacies that have introduced the system.
Why 'enpas' Maximizes Interpersonal Service Performance and Additional Fee Acquisition?
The reason is that 'enpas' 'standardizes' and 'streamlines' 'interpersonal services,' which have previously depended on pharmacists' experience and administrative workload. By automating and visualizing the processes required for fee calculation, 'enpas' provides a system that transforms person-dependent tasks into reliable revenue while reducing the burden on staff.
1. Systematizing Information Provision at the 'Right Time'
For interpersonal services such as inhalation drug guidance fees, leftover medication management, and specific drug management and guidance fees, which will be key points in the next revision, 'enpas' automatically prints and presents checklists, side effect risks, countermeasures, RMPs (Risk Management Plans for Pharmaceuticals), and guidance sheets at optimal times based on patient prescription data.
This standardization of evidence-based guidance and reporting to hospitals (e.g., inhalation guidance evaluation forms, tracing reports) does not rely on the pharmacist's experience. Introduced stores have achieved approximately a fivefold increase in the amount of information provided to medical institutions compared to before implementation. By systemically complementing complex calculation requirements, 'enpas' supports the strengthening of a reliable revenue base.
2. Reducing Material Preparation Time by Approximately 10 Minutes Per Person, Addressing Severe Staff Shortages
By supporting the preparation of guidance sheets and checklists according to prescriptions, it reduces material preparation time by approximately 10 minutes per prescription. For example, a pharmacy with 100 relevant prescriptions per month has been able to save approximately 16 hours of work time per month (equivalent to the work of about two pharmacists).
In a business environment that demands optimization of human resources, such as the newly established 'Dispensing Base-up Fee,' the time saved can be allocated to interpersonal services. Furthermore, the system's check functions prevent 'omitted claims' at the site, supporting a reliable increase in revenue.
3. Improving Medication Adherence and Increasing Repeat Visits through 'Community Pharmacy' Engagement
By providing personalized symptom checks, follow-ups, and next visit date suggestions, 'enpas' enhances patient understanding, preventing missed doses and self-discontinuation of medication. High-quality communication serves as a differentiator for pharmacies aiming to be 'chosen by the community,' realizing a stable management foundation as an infrastructure for community healthcare.
'enpas' will continue to promote the creation of systems that understand the needs of each individual patient and deliver the right information to the right people at the right time, together with introducing pharmacists. We aim to realize a society where patients can continue their treatment with peace of mind by maximizing pharmacists' expertise through the power of digital technology.
About enpas
The DX solution for dispensing pharmacies, 'enpas,' promotes DX in pharmacies. With features such as advance prescription reception and patient-specific content printing, it supports improved operational efficiency and enhanced quality of medication guidance through appropriate information provision to patients, thereby supporting the transition to 'community pharmacies' that are close to patients.
About DigiQ Inc.
DigiQ Inc. promotes DX in the retail and healthcare sectors using digital technology. The company operates a Retail DX business that provides DX solutions for the retail industry utilizing native apps and LINE mini-apps, and a Healthcare DX business that supports pharmacists in enhancing their interpersonal services through the DX solution 'enpas' for dispensing pharmacies. Through the development and operation of products that solve industry-specific challenges with digital technology, DigiQ Inc. contributes to the realization of a sustainable society.
【DigiQ Inc.】
CEO: Kazuyuki Furuya
COO: Yusuke Imai
Capital: 10 million yen
Established: December 1, 2020
Location: Toranomon Hills Station Tower 36F, 2-6-1 Toranomon, Minato-ku, Tokyo
Business Activities: Retail DX Business / Healthcare Business
FAQ
What is the cumulative number of patients who have received health support information through 'enpas'?
As of March 2026, we have surpassed a cumulative total of 10 million patients.
What specific tasks does 'enpas' streamline?
'enpas' automates and visualizes the preparation of guidance sheets and checklists according to prescriptions, information provision to hospitals, and the process for claiming specific drug management and guidance fees, thereby reducing the administrative workload for pharmacists.
How does 'enpas' help with the 2026 dispensing fee revision?
As the evaluation of interpersonal services becomes stricter, 'enpas' contributes to the stabilization of pharmacy management by systematizing high-quality interventions and supporting the acquisition of additional fees.
Are there specific effects from introducing 'enpas'?
There are cases where information provided to medical institutions has increased approximately fivefold, and material preparation time has been reduced by about 10 minutes per prescription. Furthermore, improvements in medication adherence and increased repeat visits due to becoming a community pharmacy are also expected.